Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results

1 hour ago 3

Article content

The following table summarizes selected key financial data.

Article content

As atDecember 31, 2025September 30, 2025December 31, 2024
 $$$
Cash896,713665,757825,621
Accounts receivable, net3,310,5374,208,4683,168,409
Prepaid and other current assets350,497181,666276,084
Inventory3,243,2573,818,9853,613,557
Current assets7,801,0048,874,8767,883,671
Note receivable234,230253,893323,653
Intangible assets653,618701,485801,625
Property and equipment1,718,1411,856,8812,047,989
Total assets10,406,99311,687,13511,056,938
Current liabilities3,348,2974,575,7073,267,785
Non-current liabilities3,245,9823,280,5203,391,892
Share capital27,754,55027,720,81527,657,591

Article content


SELECTED QUARTERLY INFORMATION

Article content

The Company’s functional currency is the US dollar (USD). The functional currency of the Company’s US subsidiary Aurora is USD.

Article content

Operating results for each quarter for the last two fiscal years are presented in the table below.  

Article content

Quarters EndDecember 31,
2024
September 30,
2025
June 30,
2025
March 31,
2025
December 31,
2024
September 30,
2024
 June 30,
2024
 March 31,
2024
 
 $$$$$$ $ $ 
Revenue5,022,8654,430,7554,497,3814,417,0274,702,3174,767,121 4,079,543 4,013,801 
Cost of goods sold(1,884,709)(1,731,357)(1,698,257)(1,854,244)(1,982,273)(1,884,637)(1,532,173)(1,529,538)
Gross profit3,138,1562,699,3982,799,1242,562,7832,720,0442,882,484 2,547,370 2,484,263 
Operating expenses3,153,6782,814,7542,971,7542,879,1143,219,1972,811,364 2,701,478 2,751,188 
EBITDAC*301,112165,600141,745(20,924)(320,360)380,117 105,522 117,171 
Net income (loss)(40,702)(141,980)(198,760)(349,678)(652,696)71,120 (154,108)(266,925)
Basic and diluted income (loss) per share**0.00(0.00)(0.00)(0.00)(0.01)0.00 (0.00)(0.00)

Article content

Article content

* EBITDAC is a non-GAAP, non IFRS measure defined as Earnings before Interest, Tax, Depreciation, Amortization and Stock based compensation. This amount includes Gains (losses) on sale of property and equipment and Other income (expense).
** Outstanding options and warrants have not been included in the calculation of the diluted loss per share as they would have the effect of being anti-dilutive.

Article content

Fourth Quarter and Fiscal Year 2025 Conference Call Details

Article content

Date and Time: Thursday, April 30, 2026, at 11:00 a.m. ET / 8:00 a.m. PT

Article content

Call-in Information: Interested parties can access the conference call by dialing (844) 861-5497 or (412) 317-5794.

Article content

Webcast: Interested parties can access the conference call via a live webcast, which is available via the following link: https://app.webinar.net/KVQZ1nlEx6w.

Article content

Replay: A teleconference replay of the call will be available until May 7, 2026, at (855) 669-9658 or (412) 317-0088, replay access code 8884512. Additionally, a replay of the webcast will be available at https://app.webinar.net/KVQZ1nlEx6w for 90 days.

Article content

Article content

About Aurora Spine

Article content

Aurora Spine Corporation (TSX Venture: ASG | OTCQB: ASAPF) is an innovative designer and manufacturer of minimally invasive spinal implants and interventional pain management technologies. Headquartered in Carlsbad, California, the company’s mission is to improve spinal surgery outcomes through simplified, integrated, and cost-effective solutions that advance patient care worldwide. Additional information can be accessed at www.aurora-spine.com.

Article content

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Article content

Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Article content

Company Contacts:

Article content

Aurora Spine Corporation

Article content

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Article content

Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com

Article content

Investor Contact:

Article content

Adam Lowensteiner
Lytham Partners
(646) 829-9702

Article content

Article content

Article content

Article content

Article content

Article content

Article content

Read Entire Article